Search

We Take Your Health to Heart

Participate in a Heart Clinical Trial

For additional information about heart clinical trials available through Heart & Vascular Clinical Trials, email us at heartclinicaltrials@shc.org.

Our Cardiovascular Coordinator will contact you within 24 hours. For some frequently asked questions about clinical trials, click here.

Find active Heart Clinical Trials below:


A

ABSORB 

  • Principal Investigator:  David Rizik, MD
  • Status:  Enrolling
  • Sponsor:  Abbott Vascular, Inc.
  • Summary:  The ABSORB III study will evaluate the safety and effectiveness of the Absorb BVS System compared to the XIENCE stent in the treatment of patients, including those with diabetes mellitus and with ischemic heart disease caused by up to two de novo native coronary artery lesions in separate epicardial vessels. This new innovation in cardiology interventional medicine to treat coronary artery disease restores blood flow to the damaged vessel and provides support so the vessel can stay open on its own. The unique property of this drug-eluting device is that it will dissolve over time allowing the vessel to resume a more normal function. The benefit to the patient is a greater chance to survive by not having to live with metal stents.

C

CANARY 

  • Principal Investigator:  David Rizik, MD
  • Status:  Enrolling
  • Sponsor:  InfraReDX, Inc.
  • Summary: Patients who have a large lipid burden at the site of an atherosclerotic blockage may experience an intra operative heart attack as a result of stenting over this lipid rich plaque. We are testing to see if the use of a distal protection device during the stenting procedure prevents this intraoperative damage. http://clinicaltrials.gov/ct2/show/NCT01268319?term=canary&rank=1

COLOR 

  • Principal Investigator:  David Rizik, MD
  • Status:  Enrolling
  • Sponsor:  InfraReDX, Inc.
  • Summary:  This is a new diagnostic catheter called a Lipiscan that uses NIR infrared technology to detect lipid core containing plaques that is not detectible with normal x-ray. LipiScan, was cleared by the FDA in 2008. This study is to observe the lipid core plaque and the variety of ways that it presents in patients. http://clinicaltrials.gov/ct2/show/NCT00831116?term=color&rank=1

TOP OF PAGE


E

EPIC-ER

  • Principal Investigator:  Krishnaswami Vijayaraghavan, MD
  • Status:  Enrolling
  • Sponsor:  EPIC Research & Diagnostics, Inc.
  • Summary:  The EPIC ClearView™ is a galvanic skin response measurement device that may assist the health care provider in rapid assessment of the systemic origin of the patient's presenting symptom(s). We are conducting a feasibility study to evaluate if it accurately distinguishes etiology of chest pain for patients who present to the hospital emergency department with this symptom. We will be comparing it to standard of care testing, such as cardiac enzymes & EKG. http://clinicaltrials.gov/ct2/show/NCT01476982?term=epic&rank=17

EXCEL

  • Principal Investigator:  Robert Riley, MD & David Rizik, MD
  • Status:  Enrolling
  • Sponsor:  Abbott Vascular
  • Summary:  To establish the safety and efficacy of the XIENCE PRIME or XIENCE V Stent System in participants with unprotected left main coronary artery disease by comparing Xience stents to coronary artery bypass graft surgery. The current standard of care treatment for these patients in Bypass Surgery. This is an international study involving approximately 165 sites worldwide. http://clinicaltrials.gov/ct2/show/NCT01205776?term=excel&rank=2

TOP OF PAGE


H

HYPONATREMIA REGISTRY

TOP OF PAGE


R

RIVER-PCI

  • Principal Investigator:  Joseph Klag, DO & Bradley Oswood, MD
  • Status:  Enrolling
  • Sponsor:  Gilead Sciences, Inc.
  • Summary:  The purpose of this study is to evaluate whether ranolazine, compared to placebo, can reduce the chance of future hospitalizations, PCI procedures or cardiac bypass surgeries to treat chest pain, when used as part of standard medical therapy in chronic angina participants with incomplete revascularization post-PCI. http://clinicaltrials.gov/ct2/show/NCT01442038?term=1. RIVER PCI&rank=1

TOP OF PAGE


T

TRANSLATE-ACS

  • Principal Investigator:  Joseph Klag, DO
  • Status:  Enrolling
  • Sponsor:  Eli Lilly and Duke Clinical Research Institute
  • Summary:  This is a prospective, observational longitudinal study to evaluate the real world effectiveness and use of prasugrel and other ADP receptor inhibitor therapies among myocardial infarction patients treated with percutaneous coronary intervention during the index hospitalization. Patient management and treatment decisions are at the discretion of the care team per routine clinical practice. Approximately 17,000 patients will be enrolled at approximately 350 sites in the United States. Follow-up will be conducted through 15 months in approximately 15,650patients. http://clinicaltrials.gov/ct2/show/NCT01088503?term=translate&rank=1

TRYTON 

  • Principal Investigator:  David Rizik, MD
  • Status:  Enrolling
  • Sponsor:  Tryton Medical, Inc.
  • Summary:  This is a Prospective, Single Blind, Randomized Controlled Study to Evaluate the Safety and Effectiveness of the Tryton Side Branch Stent™ used in Conjunction with a Drug-Eluting Stent Compared to Side Branch Balloon Angioplasty in Conjunction with a Drug-Eluting Stent in the Treatment of de novo Bifurcation Lesions within Native Coronary Circulation. The Tryton Side Branch Stent System is designed to address the procedural difficulty surrounding treatment of bifurcation lesions that are currently available with conventional coronary stents designed for straight (non bifurcation) lesions. http://clinicaltrials.gov/ct2/show/NCT01258972?term=tryton&rank=1

TOP OF PAGE


Contact Us:

If you have any other questions or concerns, please contact us as we will help guide you in the right direction.